An investigator received \\( \\$ 4,000 \\) of consulting income from a publicly traded drug company over the past 12 months. The investigator also owns stock in that company valued at \\( \\$ 2,000 \\). The investigator is submitting a grant to the National Institutes of Health that involves evaluating the effectiveness of a drug produced by the same drug company. Which of the following is true? The aggregate of the consulting income and the stock exceeds \\( \\$ 5,000 \\) and therefore is a significant financial interest. The value of stock is not calculated when determining significant financial interests. The investigator does not have a significant financial interest related to the grant because the consulting income is less than \\( \\$ 5,000 \\). The investigator does not have a significant financial interest related to the grant because the stock's value is less than \\( \\$ 5,000 \\)